SCHEDULE: FMR LLC Discloses Stake in Kiniksa Pharmaceuticals

FMR LLC, along with Abigail P. Johnson, has reported a beneficial ownership of 14.8% in Kiniksa Pharmaceuticals International PL's Class A Common Stock as of March 31, 2026.

Summary

• FMR LLC and Abigail P. Johnson have filed a Schedule 13G, indicating their beneficial ownership of Kiniksa Pharmaceuticals International PL's Class A Common Stock.
• As of March 31, 2026, the total beneficial ownership reported is 6,787,700.23 shares, representing 14.8% of the class of securities.
• FMR LLC holds sole voting power for 6,786,051 shares and sole dispositive power for 6,787,700.23 shares.
• Abigail P. Johnson is listed as having sole dispositive power for 6,787,700.23 shares.
• The filing is an amendment (Amendment No. 1) to a previous filing.
• The reporting persons are identified as FMR LLC (a holding company) and Abigail P. Johnson (an individual investor).
• Several subsidiaries of FMR LLC, including FIAM LLC, Fidelity Institutional Asset Management Trust Company, Fidelity Management & Research Company LLC, and Strategic Advisers LLC, are involved in the beneficial ownership.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it confirms a significant, established stake by a major investment firm, indicating ongoing confidence without new material information.

Positives

• Significant beneficial ownership stake of 14.8% in Kiniksa Pharmaceuticals International PL by FMR LLC and Abigail P. Johnson.
• Clear reporting of voting and dispositive power, indicating transparency in ownership.

Future Outlook

No specific future outlook or guidance is provided in this Schedule 13G filing, which primarily reports on current beneficial ownership.

Industry Context

StockSavvy.ai notes that this Schedule 13G filing by FMR LLC and Abigail P. Johnson signifies a substantial investment in Kiniksa Pharmaceuticals International PL, indicating confidence in the company's prospects within the biopharmaceutical sector. Such filings often precede or follow significant corporate events or strategic shifts.

Stakeholder Impact

• Shareholders: The filing confirms a substantial and stable ownership by a major institutional investor, which can be viewed positively for market confidence.
• Management of Kiniksa Pharmaceuticals: The significant stake held by FMR LLC may influence strategic discussions and corporate governance.
• Competitors: The filing highlights FMR LLC's investment focus within the biopharmaceutical sector.

Next Steps

• Continued monitoring of FMR LLC's beneficial ownership in Kiniksa Pharmaceuticals International PL.
• Potential for further filings if ownership levels change significantly.

Key Dates

Keywords

Schedule 13G, FMR LLC, Abigail P. Johnson, Kiniksa Pharmaceuticals International PL, Class A Common Stock, Beneficial Ownership, SEC Filing, Investment Management, Hedge Fund, Asset Management